Reply to letter to the editor by Lippi and Plebani: « The presence of anti-SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization » (THEIJID-D-22-00085)

Gargouri, Saba; Abid, Nabil; Karray-Hakim, Héla; Rebai, Ahmed

doi:10.1016/j.ijid.2022.01.059

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that the immune response to two doses of the Vaxzevria vaccine initially lags significantly behind the response induced by Comirnaty. This finding is consistent with numerous studies that have reported a mere 30% increase in antibody levels following the second dose of viral vector vaccines such as Vaxzevria/AstraZeneca, in contrast to a 300-400% increase seen with mRNA vaccines like Comirnaty/Pfizer [17,36,37]. The data also demonstrate that following the administration of a third dose to individuals previously vaccinated with Vaxzevri, Ab levels rise to values comparable to those achieved with homologous vaccination using the mRNA vaccine, as similarly observed in other studies [17,38].…”

Section: Discussionsupporting

confidence: 91%

The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up

Nicolai,

Tomassetti,

Pelagalli

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection.

show abstract